More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.
John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Concluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.
Early screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
We present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.
This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.
In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.